Kalaris net loss widens to $11.52 million in Q2 FY26
Reuters2026/08/11 12:04- Kalaris Therapeutics posted a GAAP net loss of USD 11.52 million, versus a GAAP net loss of USD 11.35 million a year earlier.
- GAAP R&D expense rose 6.85% to USD 9.02 million, while GAAP G&A expense fell 11.74% to USD 3.37 million.
- Cash, cash equivalents and marketable securities totaled USD 93.54 million, down from USD 117.98 million at Dec. 31, 2025.
- Patient dosing continues in the Phase 1b/2 TH103 study; preliminary data is expected in 1H 2027, with Phase 3 initiation targeted by year-end 2027.
- CEO Andrew Oxtoby cited new clinical-material batches with process enhancements, following expanded Phase 1a TH103 results supporting prior BCVA, OCT and PK findings.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Santander Bank: Japan GPIF does not need to adjust asset allocation policy, $62 billion may face sell-off
Analysts at Spain's Santander Bank stated that Japan’s Government Pension Investment Fund (GPIF) could potentially sell up to $62 billion worth of U.S. Treasury bonds without needing to formally adjust its asset allocation policy.
Health in Tech director Timothy Hayes sells 17,730 common shares for $16,243.80
Ocugen CEO Shankar Musunuri sells common shares worth $589,430.24
Computer Modelling Group held annual shareholder meeting
Crypto prices
More
